Murdoch Childrens Research Institute, R435 Against H.Pylori
Filed with ASX · · 3 pages · English
Recce Pharmaceuticals Ltd. on 6ix
Story so far
Earlier from Recce Pharmaceuticals
- Recce Completes Capital Raising of $27.95m
- R327 Phase I Study - Australias CMAX Clinical Facility
- Positive & Concentration-Dependent Efficacy Against COVID-19
- Recce Pharmaceuticals Receives Innovation Connections Grant
- Recce Pharmaceuticals Appoints James Graham as CEO
Later from Recce Pharmaceuticals
- HREC Approval to Start Phase I/II Burns Wound Study
- Encouraging Results Against SARS-CoV-2 Virus
- Anti-Viral Patent Granted in Japan for RECCE Anti-Infectives
- Recce Awarded AusIndustry Advanced Overseas (R&D) Finding
- RCE Awarded AusIndustry Advanced Overseas Anti-Viral Finding
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals